Sanofi has been upgraded to a "Buy" rating by UBS, with a target price of 110 euros. Analyst Carl Walton believes that the neurodermatitis drug Dupixent will drive growth for the company in the third quarter and expects further acceleration in 2025.
This positive outlook reflects confidence in Sanofi's product pipeline and market performance, particularly in the dermatology sector. The upgrade comes as the company continues to navigate the competitive landscape of the pharmaceutical industry.